Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 22
- Registration Number
- NCT00450801
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
- Conditions
- LymphomaHodgkin Lymphoma
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00439361
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
- Conditions
- Childhood Germ Cell TumorOvarian CancerTeratoma
- Interventions
- Procedure: autologous hematopoietic stem cell transplantationBiological: filgrastim
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00432094
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
- Conditions
- Hematologic Malignancies
- Interventions
- Drug: L-leucyl-L-leucine Methyl Ester (LLME)Biological: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)Procedure: Hematopoietic stem cell transplantation (HSCT)
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 14
- Registration Number
- NCT00429416
- Locations
- 🇺🇸
Thomas Jefferson University', Philadelphia, Pennsylvania, United States
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
- Conditions
- Myasthenia Gravis
- Interventions
- Biological: Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 9
- Registration Number
- NCT00424489
- Locations
- 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
- Conditions
- NauseaSarcomaVomiting
- Interventions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00410488
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: Dendritic Cell ImmunizationBiological: Intrathecal T-CellsBiological: T-Cells
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1230
- Registration Number
- NCT00338377
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
- Conditions
- Lymphoma, Non-HodgkinAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 150
- Registration Number
- NCT00324467
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00290433
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
- Conditions
- MYOPATHY
- Interventions
- Biological: Hematopoietic stem cell transplantationDrug: ATG(rabbit)
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 7
- Registration Number
- NCT00278564
- Locations
- 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.